ArticleAging and disease2024
Circulating Endocannabinoids and Cognitive Function in Older Adults.
Article in Aging and disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between neurodevelopmental disorders in congenital heart disease and changes in circulatory metabolites and gut microbiota composition.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The role of endogenous cannabinoids (endocannabinoids; eCBs) in cognitive-related processes has been demonstrated in preclinical studies. However, observational studies are lacking. We examined the associations of multiple circulating eCBs and eCB-like molecules with cognitive function in a sample of dementia-free older adults. In this exploratory, cross-sectional study, serum levels of 44 eCBs were analyzed in 237 older participants of the Framingham Heart Study Offspring cohort who attended examination cycle 9 (2011-2014). Linear regression models were used to examine the associations of eCB levels with cognitive function while adjusting for potential confounders and correcting for multiple testing. Effect modification by sex and apolipoprotein ɛ4 (ApoEɛ4) was additionally examined. Participants' mean age was 73.3±6.2y and 40% were men. After correction for multiple comparisons, increased levels of linoleic acid, linolenic acid, oleic acid, oleoyl alanine and palmitoyl alanine were associated with poorer executive function (B±SE=-0.0002±0.0001, p=0.002; B±SE=-0.0005±0.0001, p<0.001; B±SE=-0.0002±0.0001, p=0.003; B±SE=-0.74±0.25, p=0.003 and B±SE=-1.75±0.62, p=0.005, respectively). In addition, elevated levels of linolenoyl amide and linoleoyl amide were associated with poorer verbal memory (B±SE=-1.45±0.44, p=0.001 and B±SE=-0.16±0.05, p<0.001, respectively) and attention (B±SE=-0.12±0.04, p<0.001 and B±SE=-0.013±0.004, p<0.001, respectively). A significant interaction with sex was observed such that most of the above associations were present only among women. Furthermore, associations between several eCBs and perceptual organization were observed only among participants with ApoEɛ4 genotype. We identified novel eCB compounds that may be related to cognitive function. Validation of these findings is warranted and should consider sex and ApoEɛ4 interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.